Made Scientific and Streamline Bio Validate AI-Driven Robotics for Cell Therapy

Made Scientific and Streamline Bio have successfully validated Streamline Bio's AI-driven precision robotics platform in a live cell therapy production environment, announced in a press release. This collaboration aims to address critical challenges in cell and gene therapy (CGT) manufacturing, such as complexity, high costs, and variable quality.

The platform, designed to be flexible and adaptable across diverse equipment and protocols, automates manual, labor-intensive processes, reducing operator burden and mitigating human error. It also enables full data traceability through its digital-first design. Following the initial validation at Made Scientific's Princeton, NJ facility, the companies are advancing towards GMP integration and launching early-adopter programs.

As part of the next phase, the platform will be integrated into Made Scientific's GMP cleanrooms, utilizing systems like Miltenyi CliniMACS Prodigy, G-Rex, and Fresenius-Kabi LOVO. This integration aims to demonstrate seamless orchestration of complex workflows, setting the stage for commercial-scale implementations. Future studies will explore additional unit operations and use cases, including automated analytical and quality control testing workflows.